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A 53-year-old, gravida 2, para 1, woman with no history of
major systemic disease, presented to our clinic with a painless
right neck mass, which she had noticed 2e3 months previously.
She received a health examination and elevated CA-125 level (513
Unit/mL) was found. She then underwent a positron emission
tomographyecomputed tomography (PET/CT) scan, which
revealed suspected metastatic lymphadenopathy, including para-
aortic, pericaval, and subaortic lymph nodes of the abdomen
[maximum standardized uptake value (SUVmax): 6.1], bilateral
iliac lymph nodes (SUVmax: 11.1), and right supraclavicular lymph
nodes (SUVmax: 7.6) (Figure 1). She visited our ear, nose, and
throat clinic and a nodule ~1 cm in diameter over the right side
supraclavicular region was found, so excisional biopsy was per-
formed. The pathology revealed metastatic adenocarcinoma,
moderately to poorly differentiated; immunohistochemistry stain
disclosed CK7 (þ), CK20 (), TTF-1 (), WT-1 (þ) of suspected
gynecologic origin.* Corresponding author. Taichung Veterans General Hospital, 1650, Section 4,
Taiwan Boulavard, Xitun District, Taichung City 407, Taiwan.
E-mail address: chlu@vghtc.gov.tw (C.-H. Lu).
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(http://creativecommons.org/licenses/by-nc-nd/4.0/).She was then referred to our obstetrics and gynecology clinic.
Bimanual examination revealed a normal-sized uterus and bilateral
free adnexa without palpable mass. Ultrasonography only showed
small uterine myoma.
Laboratory tests, including a blood cell count, biochemistry, and
chest x-ray were all within normal limits, but the CA-125 level was
409 (Unit/mL). Abdominopelvic and chest CT scans were per-
formed, which also revealed multiple retroperitoneal lymph nodes,
compatible with the ﬁnding of the PET/CT scan. There was no evi-
dence of mediastinal metastasis.
Under the impression of ovarian high grade serous carcinoma
with multiple lymph node metastases, the patient then under-
went a debulking operation, including total hysterectomy,
bilateral salpingo-oophorectomy, pelvic lymph node dissection,
para-aortic lymph node sampling, appendectomy, and omen-
tectomy. The size of the uterus was normal with multiple small
uterine myomata. On cutting, no obvious endometrial tumor
was found. Bilateral ovaries and fallopian tubes were grossly
normal. Enlarged, ﬁxed, and ﬁrm lymph nodes were found over
the bilateral external obturator, common iliac, presacral, pre-
caval, and para-aortic areas up to the level of the renal veins.
The largest one measured ~12  3  3 cm in size (Figure 2). The
other pelvic or peritoneal surfaces, including the omentum,
large and small intestines, liver, and diaphragm, were free of
tumor. There was no ascites, and the appendix looked normal.
As there was no gross residual tumor, the procedure was
designated as complete debulking. The ﬁnal pathological diag-
nosis was primary serous tubal intraepithelial carcinoma (serous
carcinoma in situ) of the left fallopian tube (Figures 3A and 3B)
with multiple lymph node metastases (Figures 4Ae4C); the
vagina cut end, cervix, uterus, bilateral ovaries, and right fallo-
pian tube were free of tumor.
The patient’s stage was assessed as International Federation of
Gynecology and Obstetrics (2010) Stage IV. After the ﬁrst post-
operative week, the patient received six consecutive courses ofy Elsevier Taiwan LLC. This is an open access article under the CC BY-NC-ND license
Figure 1. Whole body PET/CT scan. Anterior projection image of PET/CT scan with F-18 ﬂudeoxyglucose (FDG) showed increased FDG activity at the para-aortic, pericaval, and
subaortic of abdomen, the bilateral iliac, and the right supraclavicular regions (arrow), indicating metastatic lymphadenopathy. In addition, a metastatic lymph node at the left
supraclavicular region was also suspected (arrow head). CT ¼ computed tomography; PET ¼ positron emission tomography.
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Myers Squibb, Wallingford, CT, USA) and carboplatin (Paraplatin,
Bristol-Myers Squibb, Princeton, NJ, USA) with an area under the
curve of 5 mg/mL/min, administered at 3-week intervals. The pa-
tient received regular follow-up at our clinic with pelvic exami-
nations, CA-125 monitoring, chest x-rays, and abdominopelvic CT
scans and has been disease-free for ~17 months since surgery.
Serous tubal intraepithelial carcinoma (STIC) presents as
a noninvasive, serous carcinoma in the fallopian tube. Besides
strong overexpression of p53 mutations, STIC is characterized by
increased nuclear/cytoplasmic ratio, enlarged nuclear pleomor-
phism with prominent nucleoli, and lack of cell polarity without
ciliated cells. Lesions with strong p53 expression and less severe
atypia are termed serous tubal intraepithelial lesions or low-
grade serous tubal intraepithelial neoplasia. Further investiga-
tion is needed to differentiate these two atypias from STIC [1,2].
The diagnosis of STIC mainly derives from the pathologic
ﬁndings of BRCA gene germline mutation carriers who have
received risk-reducing salpingo-oophorectomy and the short-
term outcome is favorable [2]. Accumulating evidences, based
on histology, immunohistochemistry, and molecular changes,
indicate that STIC may be the precursor of pelvic high grade
serous carcinoma. One of the most important useful markers for
STIC is p53, a protein which encoded by the TP53 gene. It isreported that the mutations of TP53 gene occur in 96% of pelvic
high grade serous carcinoma [3]. In addition to manifestation of
p53 mutations, PAX8, a Müllerian marker, is also expressed in
ovarian serous carcinoma [4]. Strong expression of p53 and PAX8
of lymph node in this case suggested that STIC is the source of
pelvic high grade serous carcinoma.
It has been reported that pelvic high grade serous carcinoma
usually presents at an advanced stage, grows rapidly and has
poor prognosis. Approximately 10e15% of STIC lesions were
detected in BRCA mutation carriers or in patients with a strong
history of ovarian cancer who received risk-reducing salpingo-
oophorectomy [5]. Besides, a coexisting STIC was found in
~50e60% of sporadic pelvic high grade serous carcinomas [5]. It
is proposed that the tumor cells from in situ lesions may shed to
the ovaries and the surrounding pelvic area, then ﬁnally turn
malignant [1,5,6]. However, no direct evidence of the mechanism
of STIC progression to invasive serous carcinoma has been re-
ported. Since carcinoma in situ has no contact with blood vessels,
the question of whether in situ carcinomas have the ability to
shed tumor cells into the blood circulation is still unclear. It is
known that the most common type of preinvasive breast cancer
is ductal carcinoma in situ (DCIS), in which malignant cells pro-
liferate without invasion across the basement membrane. How-
ever, recent studies revealed that disseminated tumor cells may
Figure 2. Operative ﬁnding. Enlarged, ﬁxed, and ﬁrm lymph nodes over the bilateral external obturator, common iliac, presacral, precaval, and para-aortic areas up to the level of
the renal veins. The largest one measured ~12  3  3 cm in size.
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with DCIS [7,8].
The overall survival rate of ovarian cancer when treated in
medical centers is 40e50% at 10 years, and the survival rate at
Stage IV is less than 6% [6,9]. Our patient has been followed upFigure 3. Serous tubal intraepithelial carcinoma (STIC) (400). (A) 400 Hematoxylin and e
marked nuclear pleomorphism, increased nuclear/cytoplasmic ratio, prominent nucleoli, anregularly at our clinic for ~17 months without evidence of
recurrence.
To the best of our knowledge, this is the ﬁrst report of primary
STIC with distal metastases but without pelvic serous carcinoma.
This case provides further evidence that pelvic serous carcinomaosin stain shows that the tubal epithelium is stratiﬁed and nonciliated. It also discloses
d loss of cell polarity; (B) strong immunohistochemical staining for p53 protein.
Figure 4. Metastatic adenocarcinoma in neck lymph node (400). (A) 400 Hematoxylin and eosin stain shows metastatic adenocarcinoma with papillary and micropapillary
pattern inﬁltrates in the neck lymph node; (B) strong immunohistochemical staining for p53 protein; and (C) PAX8 protein.
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that in situ carcinoma has the potential of distant metastasis.
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